MOLBIO DIAGNOSTICS LIMITED
₹ 768 - ₹ 807
10-Aug-2026 - 12-Aug-2026
₹ 14526.00

/ 18 Shares

MOLBIO DIAGNOSTICS LIMITED

10-Aug-2026 - 12-Aug-2026

₹ 768 - ₹ 807

Price Band

₹ 14526.00

Minimum Investment

18

Bid Lot

11,646,246

Shares

  • Face Value - ₹ 1/- Per Share

  • Listing at NSE BSE

  • 226,055 Application Required in Retail for 1 Time.

  • Registrar : KFin Technologies Limited

IPO Details

Fresh Issue of Equity Shares aggregating upto RS 200 Cr and Offer for Sale of 91,66,000 Equity Shares

Category % Shares/Amount
QIB 50% 5,812,862 Shares RS.469.10 CR
HNI 1 5% 581,287 Shares RS.46.91 CR @ 2307 FORM 1X
HNI 2 10% 1,162,573 Shares RS.93.28 CR @ 4613 FORM 1X
Retail 35% 4,069,005 Shares RS.328.37 CR @ 226056 FORM 1X
Employee 0% 20,519 Shares RS.1.50 CR

BRLMs: Kotak Mahindra Capital, IIFL Capital, Jefferies India, Motilal Oswal

Application Require for 1 Time

Retail (Upto 2 Lakh) HNI (2 Lakh to 10 Lakh) HNI (Above 10 Lakh)
226056 FORM 1X 2307 FORM 1X 4613 FORM 1X

IPO Lot Size

Category Lots Shares Amount
Retail (Upto 2 Lakh) 1 18 ₹ 14,526
Retail (Upto 2 Lakh) 13 234 ₹ 188,838
S-HNI (2 Lakh to 10 Lakh) 14 252 ₹ 203,364
S-HNI (2 Lakh to 10 Lakh) 68 1224 ₹ 987,768
B-HNI (Above 10 Lakh) 69 1242 ₹ 1,002,294

IPO Timeline

  • Open Date

    10-Aug-2026

  • Close Date

    12-Aug-2026

  • Basis of Allotment Date

    13-Aug-2026

  • Initiation of Refunds

    14-Aug-2026

  • Credit Shares to Demat A/c

    14-Aug-2026

  • IPO Listing Date

    17-Aug-2026

About Company

  • q Incorporated in October 2000, Molbio Diagnostics is a pioneering point-of-care company delivering rapid, cost-effective healthcare solutions for infectious and non-communicable diseases.
  • q Its flagship Truenat platform, a battery-operated PCR system patented in 100+ countries, enables decentralized diagnosis within an hour and supports 30 diseases with 43 assays, including TB, COVID, Hepatitis B and C, HIV, and HPV. The Truenat TB test chip is one of only two rapid molecular tests globally endorsed by the WHO for initial TB diagnosis and rifampicin resistance detection.
  • q Subsidiaries Prognosys Medical Systems and OptraScan Inc, along with partner UE Lifesciences, expand Molbio’s reach into radiology, digital pathology, and breast health.
  • q The platform integrates the Trueprep device for nucleic acid extraction and the Truelab analyzer (UnoDx, Duo, Quattro), supported by ready-to-use Truenat test kits. By March 2026, over 12,500 devices were sold in 90+ countries, strengthening Molbio’s global footprint.
  • q The company holds 16 patents in India and 191 abroad, reflecting its innovation strength. Strategic acquisitions include Prognosys and OptraScan, while collaborations span Testi Technologies for saliva-based alcohol testing and veterinary diagnostics.
  • q Manufacturing spans six facilities across Goa, Bengaluru, Visakhapatnam, and Pune, with installed capacity of 5,400 devices and 3.90 crore kits annually. Utilization rates between 20%–59% highlight scalability potential. Compliance is ensured through ISO 13485 and MDSAP certifications, meeting CDSCO, EU, Brazil, Canada, and US FDA standards.
  • q Leadership is spearheaded by CEO Sriram Natarajan and CTO Chandrasekhar Nair, backed by investors Motilal Oswal AIA and Temasek Holdings. Together, they reinforce Molbio’s expansion strategy, combining innovation, strong R&D, global partnerships, and manufacturing scale to address critical healthcare challenges worldwide while positioning the company as a global leader in molecular diagnostics.
Read More

Strengths

Competitive Strength 

Business Strategies 

Company Promoters

Company Financials

Molbio Diagnostics Ltd.'s revenue increased by 42% and profit after tax (PAT) rose by 18% between the financial year ending with March 31, 2026 and March 31, 2025.

Period Ended 31 Mar 2026 31 Mar 2025 31 Mar 2024
Assets 2,148.42 1,461.56 1,221.06
Total Income 1,455.17 1,027.94 840.66
Profit After Tax 164.14 138.58 83.54
EBITDA 328.24 256.64 185.09
NET Worth 1,144.68 952.95 807.94
Reserves and Surplus 1,148.84 990.84 845.48
Total Borrowing 412.64 123.16 174.58
Amount in ? Crore

Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

# Issue Objects Est Amt (? Cr.)
1 Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space. 125.12
2 Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and 80.81
3 General Corporate Purposes  
  Total 205.93
     
     

How to Apply

Apply for IPO in few simple steps.

  • Step 01 :

    Once you create your account, Login to InvestoYard.

  • Step 02 :

    Under IPO Section, you will be able to see a list of Ongoing IPOs, where you can click on apply button.

  • Step 03 :

    Add quantity of shares to apply – Maximum 3 bids are allowed (For retail category – max amount Rs.2,00,000/-).

  • Step 04 :

    Enter your UPI ID and you will receive mandate on your UPI App.

  • Step 05 :

    Once you accept the mandate, Application is submitted successful.

  • Applying for an IPO is easier than ever with InvestoYard, in just a few clicks your application is processed. You can bid for any IPO through InvestoYard, the bidding process is simple and hassle free. Every company has a lot size decided & you can buy in multiples of the decided lot.
  • If lot size is 15, then you have to bid for multiples of 15 share like 30,45,60 and so on.
  • The maximum subscription amount for retail investors is 2 lakh.
  • Any bid can be at a desired price or cut off price given by the company.

  • Enter the number of shares you wish to buy, as per the lot size.
  • You can apply at the cut off price set by the company or bid for a desired amount within the price band.
  • Maximum three bids will be accepted.
  • You then need to enter the UPI ID on InvestoYard’s IPO application form.

  • You will immediately get a fund blocked request on your UPI for the submitted IPO application.
  • The funds will be blocked in your bank account until allotment when it is debited.
  • The limit for IPO application is Rs 2 lakh per transaction on UPI.
  • On allotment of the shares, the money will be automatically debited.
  • If the share aren’t allotted the blocked funds will reflect back into your account.

Frequently Asked Questions

Apply Now